J&J and Roche Lead in S&P Ratings for Pharmaceutical Companies

Johnson & Johnson (NYSE:JNJ) and Roche (OTCQX:RHHBY) have emerged as the cream of the crop among pharmaceutical giants, boasting the lowest business and financial risks based on a recent S&P Global report.

These juggernauts, J&J and Roche, excelled in terms of magnitude and blockbuster medications compared to their industry peers.

S&P’s evaluation of business strength encompassed factors like competitive advantage (market position, barriers to entry, level of competition), sustainability of revenue growth, scale, diversity (product, therapeutic, geographic, customer), operational efficiency, and analysis of EBITDA margin stability.

The report emphasizes, “We emphasize competitive advantage (stemming from significant innovations) that can be maintained long-term, allowing for premium pricing and product distinctiveness.”

Novo Nordisk (NVO) secured the second-best business risk rating while achieving the lowest possible financial risk. Other top performers include Sanofi (SNY), Novartis (NVS), and AstraZeneca (AZN), all exhibiting a robust business risk profile with a commendable financial risk profile.

This review surveyed 17 of the world’s most prominent pharmaceutical companies.

S&P highlighted a marginal decline in overall business strength within the pharmaceutical industry in recent years, attributed to industry and regulatory shifts.

Interestingly, the companies delivering the highest stock returns this year, such as Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN), known for products like GLP-1 drugs, Eylea, and Dupixent, did not secure top spots in the strength ratings.